Ann: SARAH Clinical Study Results Investor Presentation, page-26

"One little fly in the ointment here is that the QoL is only significant in the ITT group and not the PP."

The last question in the conference call touched on that issue. Management stated that they only presented what the investigator had presented at the conference. Management seemed to indicate that it was effectively based on what treatment was received, i.e. per protocol, though on pages 23-26 of presentation, it seems there were 26 patients who received sorafenib instead of SIRT, but were included in the SIRT saftey profile; consistent with ITT protocol.

But there is no PP presented for safety, so how did you assert "QoL is only significant in the ITT group and not the PP."

If anything, the PP data will be stronger given over 10% of the SIRT patient safety profile presented were hampered by being treated with sorafenib.